• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Elanco Animal Health Set to Join S&P MidCap 400; Sarepta Therapeutics to Join S&P SmallCap 600

    8/26/25 6:15:00 PM ET
    $BHLB
    $BRKL
    $ELAN
    $SPGI
    Banks
    Finance
    Savings Institutions
    Finance
    Get the next $BHLB alert in real time by email

    NEW YORK, Aug. 26, 2025 /PRNewswire/ -- Elanco Animal Health Inc. (NYSE:ELAN) will replace Sarepta Therapeutics Inc. (NASD: SRPT) in the S&P MidCap 400, and Sarepta Therapeutics will replace Brookline Bancorp Inc. (NASD: BRKL) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, September 2. S&P SmallCap 600 constituent Berkshire Hills Bancorp Inc. (NYSE:BHLB) is acquiring Brookline Bancorp in a deal expected to be completed soon, pending final closing conditions. Post merger, Berkshire Hills Bancorp will remain in the S&P SmallCap 600 with a name and ticker change to Beacon Financial Corp. (NYSE:BBT).

    Following is a summary of the changes that will take place prior to the open of trading on the effective date:

    Effective Date 

    Index Name 

    Action 

    Company Name 

    Ticker 

    GICS Sector 

    September 2, 2025 

    S&P MidCap 400 

    Addition 

    Elanco Animal Health 

    ELAN 

    Health Care 

    September 2, 2025 

    S&P MidCap 400

    Deletion 

    Sarepta Therapeutics 

    SRPT 

    Health Care 

    September 2, 2025 

    S&P SmallCap 600 

    Addition 

    Sarepta Therapeutics 

    SRPT 

    Health Care 

    September 2, 2025 

    S&P SmallCap 600

    Deletion

    Brookline Bancorp

    BRKL

    Financials

    For more information about S&P Dow Jones Indices, please visit www.spdji.com

    ABOUT S&P DOW JONES INDICES

    S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.

    S&P Dow Jones Indices is a division of S&P Global (NYSE:SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spdji.com.

    FOR MORE INFORMATION:

    S&P Dow Jones Indices

    [email protected] 

    Media Inquiries

    [email protected] 

    Cision View original content:https://www.prnewswire.com/news-releases/elanco-animal-health-set-to-join-sp-midcap-400-sarepta-therapeutics-to-join-sp-smallcap-600-302539403.html

    SOURCE S&P Dow Jones Indices

    Get the next $BHLB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BHLB
    $BRKL
    $ELAN
    $SPGI

    CompanyDatePrice TargetRatingAnalyst
    Sarepta Therapeutics Inc.
    $SRPT
    1/28/2026$20.00Equal Weight
    Barclays
    Elanco Animal Health Incorporated
    $ELAN
    1/22/2026Neutral → Overweight
    Piper Sandler
    Sarepta Therapeutics Inc.
    $SRPT
    12/9/2025$32.00Outperform
    Wedbush
    Elanco Animal Health Incorporated
    $ELAN
    12/9/2025$30.00Overweight
    Barclays
    Elanco Animal Health Incorporated
    $ELAN
    11/21/2025$27.00Overweight
    KeyBanc Capital Markets
    Elanco Animal Health Incorporated
    $ELAN
    11/19/2025$25.00Hold → Buy
    Argus
    Sarepta Therapeutics Inc.
    $SRPT
    11/5/2025$26.00Neutral → Outperform
    Mizuho
    Elanco Animal Health Incorporated
    $ELAN
    10/7/2025$24.00Neutral → Overweight
    Analyst
    More analyst ratings

    $BHLB
    $BRKL
    $ELAN
    $SPGI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President, S&P Global Mobility Eager William W exercised 254 shares at a strike of $527.79 and covered exercise/tax liability with 115 shares, increasing direct ownership by 2% to 8,863 units (SEC Form 4)

    4 - S&P Global Inc. (0000064040) (Issuer)

    2/3/26 4:02:18 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    Director Nicaise Claude exercised 10,500 shares at a strike of $13.71 and covered exercise/tax liability with 6,780 shares, increasing direct ownership by 13% to 31,532 units (SEC Form 4)

    4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)

    1/29/26 8:05:03 PM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Behrens M Kathleen exercised 10,500 shares at a strike of $13.71 and covered exercise/tax liability with 6,494 shares, increasing direct ownership by 2% to 197,482 units (SEC Form 4)

    4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)

    1/29/26 8:04:03 PM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHLB
    $BRKL
    $ELAN
    $SPGI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for AMONDYS 45 issued to SAREPTA THERAPS INC

    Submission status for SAREPTA THERAPS INC's drug AMONDYS 45 (SUPPL-8) with active ingredient CASIMERSEN has changed to 'Approval' on 07/11/2024. Application Category: NDA, Application Number: 213026, Application Classification: Labeling

    7/12/24 4:40:36 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    June 20, 2024 - FDA Expands Approval of Gene Therapy for Patients with Duchenne Muscular Dystrophy

    For Immediate Release: June 20, 2024 Today, the U.S. Food and Drug Administration expanded the approval of Elevidys (delandistrogene moxeparvovec-rokl), a gene therapy for the treatment of Duchenne muscular dystrophy (DMD) for ambulatory and non-ambulatory individuals 4 years of age and older with DMD with a confirmed mutation in the DMD gene.  Elevidys was previously approved under accelerated approval for amb

    6/20/24 5:24:42 PM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VYONDYS 53 issued to SAREPTA THERAPS INC

    Submission status for SAREPTA THERAPS INC's drug VYONDYS 53 (SUPPL-11) with active ingredient GOLODIRSEN has changed to 'Approval' on 06/04/2024. Application Category: NDA, Application Number: 211970, Application Classification: Labeling

    6/5/24 4:41:31 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHLB
    $BRKL
    $ELAN
    $SPGI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays resumed coverage on Sarepta Therapeutics with a new price target

    Barclays resumed coverage of Sarepta Therapeutics with a rating of Equal Weight and set a new price target of $20.00

    1/28/26 7:19:11 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Animal Health upgraded by Piper Sandler

    Piper Sandler upgraded Elanco Animal Health from Neutral to Overweight

    1/22/26 8:20:23 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wedbush initiated coverage on Sarepta Therapeutics with a new price target

    Wedbush initiated coverage of Sarepta Therapeutics with a rating of Outperform and set a new price target of $32.00

    12/9/25 8:53:25 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHLB
    $BRKL
    $ELAN
    $SPGI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President, S&P Global Mobility Eager William W bought $11,917 worth of shares (23 units at $517.58), increasing direct ownership by 0.26% to 8,724 units (SEC Form 4)

    4 - S&P Global Inc. (0000064040) (Issuer)

    1/15/26 4:01:18 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    Director Kurzius Lawrence Erik bought $213,000 worth of shares (10,000 units at $21.30), increasing direct ownership by 8% to 131,773 units (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    12/16/25 4:42:47 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PRESIDENT, CEO AND DIRECTOR Simmons Jeffrey N bought $478,496 worth of shares (22,000 units at $21.75) (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    12/15/25 4:41:24 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHLB
    $BRKL
    $ELAN
    $SPGI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    S&P Global Introduces New Brand Identity for Mobility Division as "Mobility Global"

    New Brand Reflects the Business as the Global Standard for Automotive Intelligence; Will Be Used Upon Separation as Standalone Public Company NEW YORK, Feb. 3, 2026 /PRNewswire/ -- S&P Global (NYSE:SPGI) today announced Mobility Global, Inc ("Mobility Global") will be the corporate name for the S&P Global Mobility business upon completion of its planned separation from S&P Global into a standalone public company. The Mobility Global name reflects its leadership in providing critical intelligence across the vehicle lifecycle to suppliers, OEMs, dealers, and consumers worldwide.

    2/3/26 8:00:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600

    NEW YORK, Jan. 27, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400, S&P SmallCap 600: S&P SmallCap 600 constituent TTM Technologies Inc. (NASD: TTMI) will replace Civitas Resources Inc. (NYSE:CIVI) in the S&P MidCap 400, and Amneal Pharmaceuticals Inc. (NASD: AMRX) will replace TTM Technologies in the S&P SmallCap 600 effective prior to the opening of trading on Friday, January 30. S&P SmallCap 600 constituent SM Energy Co. (NYSE:SM) is acquiring Civitas Resources in a deal expected to be completed soon, pending final closing conditions. SM Energy will remain in the S&P SmallCap 600 post-merger.Dutch Bros Inc. (NYSE:BROS) will replace Potlatc

    1/27/26 6:02:00 PM ET
    $AEIS
    $AHR
    $AMRX
    Industrial Machinery/Components
    Technology
    Real Estate Investment Trusts
    Real Estate

    S&P Cotality Case-Shiller Index Reports Annual Gain In November 2025

    The S&P Cotality Case-Shiller U.S. National Home Price NSA Index posted a 1.4% annual gain for November, in line with the previous month.Real home values declined as consumer inflation (2.7%) outpaced the National Index gain (1.4%) by 1.3 percentage points.Regional divergence persisted: Midwestern and Northeastern markets led by Chicago (+5.7%) and New York (+5.0%) posted gains, while Sun Belt cities including Tampa (–3.9%), Phoenix (–1.4%), Dallas (–1.4%), and Miami (–1.0%) saw declines.NEW YORK, Jan. 27, 2026 /PRNewswire/ -- S&P Dow Jones Indices (S&P DJI) today released the November 2025 results for the S&P Cotality Case-Shiller Indices. More than 27 years of history are available for th

    1/27/26 9:45:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    $BHLB
    $BRKL
    $ELAN
    $SPGI
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Elanco Animal Health Incorporated

    SCHEDULE 13G - Elanco Animal Health Inc (0001739104) (Subject)

    1/21/26 1:21:12 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: S&P Global Inc. filed SEC Form 8-K: Leadership Update

    8-K/A - S&P Global Inc. (0000064040) (Filer)

    1/14/26 4:15:07 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    Sarepta Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Sarepta Therapeutics, Inc. (0000873303) (Filer)

    1/12/26 12:05:31 PM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHLB
    $BRKL
    $ELAN
    $SPGI
    Leadership Updates

    Live Leadership Updates

    View All

    TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600

    NEW YORK, Jan. 27, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400, S&P SmallCap 600: S&P SmallCap 600 constituent TTM Technologies Inc. (NASD: TTMI) will replace Civitas Resources Inc. (NYSE:CIVI) in the S&P MidCap 400, and Amneal Pharmaceuticals Inc. (NASD: AMRX) will replace TTM Technologies in the S&P SmallCap 600 effective prior to the opening of trading on Friday, January 30. S&P SmallCap 600 constituent SM Energy Co. (NYSE:SM) is acquiring Civitas Resources in a deal expected to be completed soon, pending final closing conditions. SM Energy will remain in the S&P SmallCap 600 post-merger.Dutch Bros Inc. (NYSE:BROS) will replace Potlatc

    1/27/26 6:02:00 PM ET
    $AEIS
    $AHR
    $AMRX
    Industrial Machinery/Components
    Technology
    Real Estate Investment Trusts
    Real Estate

    Winmark Set to Join S&P SmallCap 600

    NEW YORK, Jan. 21, 2026 /PRNewswire/ -- Winmark Corp. (NASD: WINA) will replace Guess? Inc. (NYSE:GES) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, January 26. Authentic Brands Group LLC and the Rolling Stockholders are acquiring Guess? in a deal expected to close soon pending final closing conditions. Following is a summary of the change that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector Jan 26, 2026 S&P SmallCap 600 Addition Winmark WINA Consumer Discretionary Jan 26, 2026 S&P SmallCap 600 Deletion Guess? GES Consumer Discretionary ABOUT S&P DOW JONES INDICES S&P Dow Jone

    1/21/26 6:01:00 PM ET
    $GES
    $SPGI
    $WINA
    Apparel
    Consumer Discretionary
    Finance: Consumer Services
    Finance

    StandardAero Set to Join S&P MidCap 400

    NEW YORK, Jan. 16, 2026 /PRNewswire/ -- StandardAero Inc. (NYSE:SARO) will replace Frontier Communications Parent Inc. (NASD: FYBR) in the S&P MidCap 400 effective prior to the opening of trading on Thursday, January 22. S&P 500 & S&P 100 constituent Verizon Communications Inc. (NYSE:VZ) is acquiring Frontier Communications Parent in a deal expected to close soon pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector Jan 22, 2026 S&P MidCap 400 Addition StandardAero SARO Industrials Jan 22, 2026 S&P MidCap 400 Deletion Frontier Communicati

    1/16/26 6:26:00 PM ET
    $FYBR
    $SARO
    $SPGI
    Telecommunications Equipment
    Telecommunications
    Aerospace
    Industrials

    $BHLB
    $BRKL
    $ELAN
    $SPGI
    Financials

    Live finance-specific insights

    View All

    Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients

    At a mean age of 9 years old, ELEVIDYS-treated patients achieved mean North Star Ambulatory Assessment (NSAA) scores above baseline three years after treatment (n=52) ELEVIDYS gene therapy demonstrated 70% or greater reduction in the rate of decline relative to the propensity-weighted external control group, as measured by Time to Rise (TTR) and 10-meter walk/run (10MWR). ELEVIDYS-treated patients showed an increasing treatment effect over time, with the functional gap versus the external control group significantly widening between Year 2 and Year 3 No new treatment-related safety signals were observed, consistent with the manageable safety profile observed with ELEVIDYS in ambulato

    1/26/26 8:00:00 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    S&P Dow Jones Indices Announces Changes to the S&P/TSX Canadian Dividend Aristocrats Index

    TORONTO, Jan. 23, 2026 /CNW/ - S&P Dow Jones Indices announces the following index changes as a result of the annual S&P/TSX Canadian Dividend Aristocrats Index review. These changes will be effective prior to the open of trading on Monday, February 2, 2026. S&P/TSX Canadian Dividend Aristocrats Index – February 2, 2026 Symbol COMPANY ADDED CEU CES Energy Solutions Corp. ADDED CVE Cenovus Energy Inc ADDED DOO BRP Inc. ADDED GFL GFL Environmental Inc. ADDED GIL Gildan Activewear Inc A ADDED LNR Linamar Corp ADDED MTL Mullen Group Ltd ADDED MTY MTY Food Group Inc ADDED OR OR Royalties Inc. ADDED RCH Richelieu Hardware Ltd ADDED TPZ Topaz Energy Corp. ADDED WTE Westshore Terminals Investment C

    1/23/26 5:15:00 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    Sarepta Therapeutics to Report 3-Year Topline Data from EMBARK Study of ELEVIDYS Gene Therapy in Ambulatory Individuals with Duchenne Muscular Dystrophy

    Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Monday, Jan. 26, 2026, at 8:30 am Eastern Time, the Company will host a webcast and conference call to present 3-year topline functional results from patients treated in Part 1 of EMBARK (Study 9001-301), the global, randomized placebo-controlled Phase 3 study evaluating ELEVIDYS (delandistrogene moxeparvovec-rokl) in ambulatory individuals with Duchenne muscular dystrophy who were aged four to seven at time of treatment. The event will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-presenta

    1/23/26 4:05:00 PM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHLB
    $BRKL
    $ELAN
    $SPGI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sarepta Therapeutics Inc.

    SC 13G/A - Sarepta Therapeutics, Inc. (0000873303) (Subject)

    11/13/24 10:27:59 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Brookline Bancorp Inc.

    SC 13G/A - BROOKLINE BANCORP INC (0001049782) (Subject)

    11/12/24 5:09:10 PM ET
    $BRKL
    Savings Institutions
    Finance

    Amendment: SEC Form SC 13G/A filed by Brookline Bancorp Inc.

    SC 13G/A - BROOKLINE BANCORP INC (0001049782) (Subject)

    11/12/24 10:03:30 AM ET
    $BRKL
    Savings Institutions
    Finance